Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Davis

Showing results (121-130 of 166) with videos related to

Pageof 17
Sort By:
American Journal of Hematology|February 21, 2019
Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphomaPaolo Strati, Seung Tae Lee, Purnima Teegavarupu, et al.
Blood|February 22, 2003
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profileAdrian Wiestner, Andreas Rosenwald, Todd S Barry, et al.
Leukemia|April 28, 2019
CXCR5<sup>+</sup>CD8<sup>+</sup> T cells are a distinct functional subset with an antitumor activityFuliang Chu, Haiyan S Li, Xindong Liu, et al.
Genome Biology|May 30, 2020
CICERO: a versatile method for detecting complex and diverse driver fusions using cancer RNA sequencing dataLiqing Tian, Yongjin Li, Michael N Edmonson, et al.
Blood Advances|June 15, 2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphomaNeha Akkad, Lei Feng, Jason R Westin, et al.
Blood|March 16, 2025
Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagementHaopeng Yang, Wenchao Zhang, Vida Ravanmehr, et al.
The Lancet. Oncology|December 17, 2013
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialJason R Westin, Fuliang Chu, Min Zhang, et al.
Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.
Cancer Immunology Research|September 12, 2020
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic PhenotypeAshvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, et al.
Leukemia|March 28, 2018
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myelomaXiaohui Zhang, Hans C Lee, Fazal Shirazi, et al.
Pageof 17

Showing results (121-130 of 166) with videos related to

Sort By:
Pageof 17
American Journal of Hematology|February 21, 2019
Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphomaPaolo Strati, Seung Tae Lee, Purnima Teegavarupu, et al.
Blood|February 22, 2003
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profileAdrian Wiestner, Andreas Rosenwald, Todd S Barry, et al.
Leukemia|April 28, 2019
CXCR5<sup>+</sup>CD8<sup>+</sup> T cells are a distinct functional subset with an antitumor activityFuliang Chu, Haiyan S Li, Xindong Liu, et al.
Genome Biology|May 30, 2020
CICERO: a versatile method for detecting complex and diverse driver fusions using cancer RNA sequencing dataLiqing Tian, Yongjin Li, Michael N Edmonson, et al.
Blood Advances|June 15, 2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphomaNeha Akkad, Lei Feng, Jason R Westin, et al.
Blood|March 16, 2025
Blunted CD40-responsive enhancer activation in CREBBP-mutant lymphomas can be restored by enforced CD4 T-cell engagementHaopeng Yang, Wenchao Zhang, Vida Ravanmehr, et al.
The Lancet. Oncology|December 17, 2013
Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trialJason R Westin, Fuliang Chu, Min Zhang, et al.
Cancer Cell|August 19, 2007
Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myelomaChristina M Annunziata, R Eric Davis, Yulia Demchenko, et al.
Cancer Immunology Research|September 12, 2020
Melanoma Evolves Complete Immunotherapy Resistance through the Acquisition of a Hypermetabolic PhenotypeAshvin R Jaiswal, Arthur J Liu, Shivanand Pudakalakatti, et al.
Leukemia|March 28, 2018
Protein targeting chimeric molecules specific for bromodomain and extra-terminal motif family proteins are active against pre-clinical models of multiple myelomaXiaohui Zhang, Hans C Lee, Fazal Shirazi, et al.
Pageof 17